Navigation Links
EPIX Pharmaceuticals Announces Statistically Significant Results in,Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug,Candidate

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) announced today positive cognitive function results from its Phase 1b multiple ascending dose clinical trial of PRX-07034, the company's internally-discovered, novel 5-HT6 antagonist being developed for obesity, Alzheimer's disease and cognitive impairment associated with schizophrenia.

The randomized, double-blind, placebo-controlled Phase 1b, multiple ascending dose clinical trial was designed to study the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRX-07034 administered orally once-daily for 28 days in a population of obese, but otherwise healthy, adults (average weight 100kg or 220 pounds). The 33-person trial, which was conducted in an in-patient setting, included measures to assess potential effects on cognitive function and obesity. Highlights from the study include: -0-

-- Primary endpoint: safety and tolerability.


    -- PRX-07034 was well tolerated up to 600 mg once per day. No dose

       limiting toxicity was identified, and no serious adverse events

       were reported. There were no withdrawals due to adverse events.


    -- PRX-07034 demonstrated predictable pharmacokinetics with dose

       proportional increases in exposures, and a half-life supporting

       once-daily administration.


-- Secondary endpoint: cognitive function (CogScreen(TM) test

   battery).


    -- Overall results on cognitive function showed a dose-dependent

       trend for improvement associated with PRX-07034.


    -- For the predetermined endpoint that combines speed and

       accuracy, there was a dose-dependent effect which was

       statistically significant (p=0.014 vs. placebo) at the 600 mg

       dose.


-- Additional findings: signals suggestive of pharmacologic activity

   were observed for obesity, even in the in-patient setting.


    -- A greater proportion of subjects on drug experienced weight

       loss during the o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at ... how blocking a particular molecule in metastatic breast cancer ... number of lung metastases. BRI scientists have found in ... shrink tumors by 60 - 80 percent and can ... lung. The $1.8 million five-year grant comes from the ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2
... Move Policymakers to "Thoughtful Dialogue"WASHINGTON, Feb. 11 ... the merits of the Medicare Durable Medical Equipment, ... home oxygen leaders call on legislators to carefully ... on beneficiary services and much needed service-oriented jobs. ...
... COLUMBIA, S.C., Feb. 11 The Consortium for ... business, academic and economic development organizations intended to ... board and named Lonnie Emard as the interim ... information systems at BlueCross BlueShield of South Carolina, ...
... all-digital cancer hospital enhances commitment to quality care ... Feb. 11 Cancer Treatment Centers of America ... hospital in Goodyear, Ariz. The 213,000-square-foot facility is ... network. CTCA at Western Regional Medical Center ...
... St George,s, University of London measured recent exposure to tobacco ... Regional Heart Study by measuring the levels of cotinine - ... points 20 years apart. A blood cotinine level above 0.7ng/mL ... a heart attack (2), and other studies have suggested that ...
... 2009 "The House of Representatives and the Senate ... payment, on health care reform in the economic stimulus ... American College of Physicians, said today. ... that will provide adequate funding for critical health care ...
... Feb. 11 Z Trim Holdings,(OTC Bulletin Board: ZTHO), ... Valley,s E.D. Smith "Garden Goodness",French Style Dressing is made ... panel. , E.D. Smith, a ... being,the #1 store brand supplier of pourable dressings in ...
Cached Medicine News:Health News:As Congress Debates Competitive Bidding Program, Home Oxygen Beneficiaries and Providers Left to Cope with 27 Percent Cut to Medicare Home Oxygen Benefit 2Health News:S.C.-Based Technology Consortium Names Interim Executive Director and Board 2Health News:S.C.-Based Technology Consortium Names Interim Executive Director and Board 3Health News:Electronic Health Record Advances Patient-Centered Cancer Care 2Health News:Electronic Health Record Advances Patient-Centered Cancer Care 3Health News:Smokers putting their loved ones at risk of heart attacks 2Health News:ACP commends Congress for including health care reform in economic stimulus legislation 2Health News:Bay Valley's French Style Dressing Demonstrates Z Trim's Value to Private Label and Store Brands 2Health News:Bay Valley's French Style Dressing Demonstrates Z Trim's Value to Private Label and Store Brands 3Health News:Bay Valley's French Style Dressing Demonstrates Z Trim's Value to Private Label and Store Brands 4
... The Vasculight VS system improves the ... (sun-induced freckles), most benign brown pigments, telangiectasias, ... of Intense Pulsed Light (IPLTM) treats pigmentary ... The unique, combined approach of IPL and ...
... The new IPL Quantum DL ... technology with the reliability and simplicity ... Its modular and upgradeable design protects ... the SR mode for IPL skin ...
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
Medicine Products: